San Diego – March 7, 2016 – GenomeDx Biosciences today announced that three abstracts featuring Decipher GRID (Genomics Resource Information Database) and Decipher Prostate Cancer Classifier tests will be presented at the 31st Annual EAU Congress (EAU16) held March 11-15 in Munich, Germany. The Annual EAU Congress is Europe’s largest urological event showcasing the latest […]
Category: Press Releases
New Study Demonstrates that GenomeDx’s Decipher™ Test was Superior to Current Risk Assessment Tools in Predicting Metastatic Prostate Cancer
Data Presented by at 2013 American Urological Association Annual Meeting San Diego, May 8, 2013 – GenomeDx Biosciences today announced the presentation of results of an independent validation study demonstrating that Decipher™ was a better predictor of clinical metastasis in prostate cancer patients treated with surgery than current risk assessment tools, including preoperative PSA levels, […]
New Study Shows that Genetic Information from Prostate Needle Biopsy May Be Used to Predict Tumor Aggressiveness – GenomeDx
Study published in Journal of Molecular Diagnostics shows concordance in molecular information between prostate biopsy and surgery samples analyzed with the Decipher Prostate Cancer Classifier San Diego, March 15, 2016 – GenomeDx Biosciences today announced results from a new study which demonstrates the ability to measure and evaluate biomarkers from RNA expression data obtained from […]
GenomeDx and Color Collaborate to Further Advance Precision Medicine for Prostate Cancer Patients and their Families
GenomeDx and Color to offer hereditary cancer risk genetic testing for prostate cancer San Diego and Burlingame, CA – May 12, 2017 – GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced a collaboration with Color to offer its Color Test, a hereditary cancer risk genetic test that analyzes 30 genes. […]
GenomeDx and Mayo Clinic Enter Agreement to Conduct Validation Study of Decipher® Prostate Cancer Test in Patients Receiving Biopsy Prior to Treatment
Builds on initial collaboration with Mayo Clinic that led to the development and commercialization of Decipher in patients following prostate surgery SAN DIEGO – November 11, 2014 – GenomeDx Biosciences today announced that the company has expanded its research agreement with Mayo Clinic to initiate a validation study to expand the use of the Decipher® […]
Decipher® Predicts Metastasis and Identifies Biomarkers Predictive of Aggressive Disease in African American Men
Study published by the Journal of Clinical Oncology provides biomarker insights into racial disparity in prostate cancer outcomes & shows that Decipher successfully stratifies African American men for metastasis San Diego, August 4, 2015 – GenomeDx Biosciences announced today that its commercially-available Decipher® testing platform identified, with statistical significance, a set of prostate cancer biomarkers […]
Cedars-Sinai to Join Decipher GRID through Partnership with GenomeDx
Cedars-Sinai signs on to test prostate cancer patients with Decipher Prostate Cancer Classifier under innovative data sharing program between physicians from leading cancer centers San Diego, October 13, 2015 – GenomeDx Biosciences today announced that Cedars-Sinai has partnered with the company on the Decipher® Genomics Resource Information Database (Decipher GRIDTM), a clinical genomics data sharing […]
Centers for Medicare and Medicaid Services Publishes Draft Coverage Decision to Reimburse the Decipher® Test for Intermediate & High Risk Prostate Cancer
San Diego, CA – Oct. 16, 2014 – GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical […]
GenomeDx Adds a National PPO to Make Available Decipher® Prostate Cancer Test
San Diego, September 25, 2014 – GenomeDx Biosciences today announced that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing. The agreement includes GenomeDx Biosciences’ participation in the MultiPlan Network, expanding access to the Decipher® Prostate Cancer Classifier to health plan members who access the more than 500,000 providers participating […]
GenomeDx Biosciences Launches Decipher Biopsy Test
New Predictor of Prostate Cancer Disease Progression Now Available for Newly Diagnosed Patients San Diego – March 8, 2016 – GenomeDx Biosciences today announced the launch of Decipher Biopsy, a genomic test that evaluates RNA expression-based biomarkers to predict the risk of high-grade disease, metastasis and cancer-specific death at the time of biopsy in men […]